Sector Experts

Philippa Flint

Image: Philippa Flint

Philippa Flint has more than 11 years of experience in drug development and regulatory affairs at big pharma, combined with 10 years of capital markets experience as an equity research analyst. Prior to working at Bloom Burton & Co. Flint was an equity analyst at RBC Dominion Securities, providing research coverage of small- to mid-cap biotech/pharma companies. She has been consistently ranked the top earnings estimator in Canada in the healthcare sector by StarMine, including over the period from 2004-2008 and in 2011. Prior to this, Flint was the vice president for medical affairs at AstraZeneca Canada, managing a department of 150 people working on more than 100 clinical trials. She led the merger of Astra and Zeneca in Canada, prior to which she was the vice president for regulatory affairs and corporate project management at Astra Canada. Flint holds master's of science degree and a master's degree in business administration.




Recent Interviews

Profit from Canadian-Based Biotechs and Specialty Pharmas: Philippa Flint (7/12/12) Covering a wide variety of small biotech and pharma companies domiciled in Canada, Bloom Burton & Co. Research Analyst Philippa Flint discusses important biotech and specialty pharma names that she knows quite well and expects to be very profitable for investors. In this exclusive interview with The Life Sciences Report, Flint explains in depth why her favorite companies should be in your portfolio.

Recent Quotes

"ONCY's phase 3 head and neck cancer data are still on the horizon." (10/1/13) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

"ONCY's phase 3 head and neck survival data are expected in H2/13." (5/9/13) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

"We expect data this year on the key studies for ONCY's Reolysin." (3/20/13) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

"We expect OGXI's shares to gain in value in H2/13." (3/8/13) OncoGenex Pharmaceuticals Inc. - Philippa Flint, Bloom Burton & Co. More >

"ONCY has successfully raised at least 12 months' additional cash.' (2/20/13) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

"In phase 2, ONCY showed 95% of patients had some tumor shrinkage." (2/8/13) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

"We are encouraged by ONC's early Reolysin data." (12/18/12) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

"We maintain our Buy rating on ONC given potential upside." (9/12/12) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

more comments

"In our view, ONC's benefit/risk balance lies in favor to the upside." (8/2/12) Oncolytics Biotech Inc. - Philippa Flint, Bloom Burton & Co. More >

"We reiterate our Buy rating on OGXI." (8/2/12) OncoGenex Pharmaceuticals Inc. - Philippa Flint, Bloom Burton & Co. More >

fewer comments


Due to permission requirements, not all quotes are shown.